Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
265.22
-5.23 (-1.93%)
At close: Jul 13, 2026, 4:00 PM EDT
264.00
-1.22 (-0.46%)
After-hours: Jul 13, 2026, 5:55 PM EDT
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 246.60M EUR in the quarter ending March 31, 2026, with 144.27% growth. This brings the company's revenue in the last twelve months to 865.78M, up 134.82% year-over-year. In the year 2025, Ascendis Pharma had annual revenue of 720.13M with 98.03% growth.
Revenue (ttm)
865.78M EUR
Revenue Growth
+134.82%
P/S Ratio
16.50
Revenue / Employee
728,158 EUR
Employees
1,189
Market Cap
16.47B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 720.13M | 356.49M | 98.03% |
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Dec 31, 2022 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | 13.38M | 2.79M | 26.41% |
| Dec 31, 2018 | 10.58M | 9.05M | 591.57% |
| Dec 31, 2017 | 1.53M | -3.08M | -66.78% |
| Dec 31, 2016 | 4.61M | -3.51M | -43.26% |
| Dec 31, 2015 | 8.12M | -5.87M | -41.94% |
| Dec 31, 2014 | 13.98M | -6.43M | -31.48% |
| Dec 31, 2013 | 20.41M | 4.83M | 30.96% |
| Dec 31, 2012 | 15.58M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.36B |
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.13B |
| Insmed | 819.56M |
| Axsome Therapeutics | 708.24M |
ASND News
- 6 days ago - Ascendis Pharma price target raised to $280 from $275 at RBC Capital - TheFly
- 12 days ago - 14 value stocks of companies primed for rapid growth through 2028 - Market Watch
- 13 days ago - Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial - TheFly
- 13 days ago - Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial - GlobeNewsWire
- 17 days ago - Ascendis Pharma added to multiple Russell U.S. Indexes - TheFly
- 17 days ago - Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap® - GlobeNewsWire
- 18 days ago - Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 - GlobeNewsWire
- 4 weeks ago - Ascendis Pharma completes Phase 3 PaTHway Trial - TheFly